Latest Content

Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.

Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.

From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.

Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.

Enspryng is the first subcutaneous, at-home treatment option for TED and the first IL-6 receptor inhibitor approved for this indication.

Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.

Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.

FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.

For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.